

Company Name : Pharmaniaga Berhad

Date : 3 April 2013

Source : The Star Online

Pharmaniaga In MoU To Buy Indonesian Firm For RM86.2mil

PETALING JAYA: Pharmaniaga Bhd has entered into a memorandum of understanding (MoU) with Glenn Rahyu Adli Ariff to buy 100% of PT Errita Pharma, a privately held manufacturer of generic pharmaceutical products based in Bandung, Indonesia, for US\$28mil (RM86.2mil).

The company said in a statement to the stock exchange yesterday that it planned to acquire 40,000 shares in PT Errita Pharma from two vendors, Sutjipto Tjengudororo and Hendrijanto Surjosuseno.

Under the agreement, Pharmaniaga, a 54.7%-owned unit of conglomerate Boustead Holdings Bhd, would buy 30,000 shares, or 75%, and Ariff 10,000 shares. Pharmaniaga's stake is worth US\$21mil (RM64.7mil).

Checks by *StarBiz* revealed that Ariff is a director of Jakarta Stock Exchange-listed PT Millennium Pharmacon International Tbk, in which Pharmaniaga has a 55% interest.

Pharmaniaga bought the stake in 2004, making it the Indonesian firm's largest shareholder. Pharmaniaga is also listed as one of PT Millennium Pharmacon International's clients.

According to its website, PT Millennium Pharmacon International is Indonesia's biggest independent, public-listed distributor of pharmaceutical products, food supplements and diagnostic products.

It has 29 branch offices, five sub-distributors, three pooling warehouses and 15 sales stations throughout the country, and serves principals comprising both local and multinational companies.

Its products are distributed to pharmacies, hospitals and drugstores nationwide, the company said.

The website also states that Ariff, who obtained his Bachelor of Science in Engineering Management from the University of Hertfordshire in 2002, started his career with Centralised Utilities Facilities and Ammonia Syngas Projects in Terengganu and Nova Stilm Oil in Modena, Italy.

He was involved in the Schering Plough-Multi Product Plan Project, the Takeda Pharmaceutical Ingredient Plant Project, Shell Stanlow Refinery, the Sharq Third Expansion Feed Project and the Yanbu Petrochemical Complex Project, according to *Reuters* data.

In 2006, he was a project manager for the Gurney Residence Project in Malaysia, and has since 2007 worked in a private equity firm known as Matan Sdn Bhd.

“The terms of the MoU are subject to the execution of a sale and purchase agreement by both the parties within 30 days from the date of the MoU, or by such other date as may be required by the purchasers in writing, failing which the proposal contained in the MoU shall automatically lapse and have no further effect,” Pharmaniaga said.

It added that the effects of the proposed acquisition would only be known once the terms of the purchase were finalised. Pharmaniaga ended the day up five sen to RM8.42, off its intraday high of RM8.47, on volume of 321,600 shares.